AI Clinical Trial Endpoint Tool Gains Regulatory Approval
zakkohane · x · 2026-07-19
A new Perspective article discusses the significance of an AI-enabled clinical trial endpoint tool (AIM-NASH) receiving recognition from the European Medicines Agency and the US FDA.
The accompanying image lists various potential AI applications in clinical trial endpoints, including:
- Pathology, imaging, physiological imaging as surrogate endpoints
- Symptom reports, functional assessments, event classification as clinical endpoints
- Using sensors, smartphones, and AI classification models to improve data collection and endpoint adjudication consistency
The article focuses not on a single model, but on how such tools change clinical evidence generation and endpoint adjudication processes.
More from Safety
- PNAS special issue examines copyright, governance, and AI in the legal system — chrmanning · 2026-07-22
- Pensar Launches AI Security Agent to Autonomously Discover and Patch 0-Days — andriy_mulyar · 2026-07-22
- Bloomberg says Sam Altman will brief Trump officials and Congress on GPT-6 next week — soumitrashukla9 · 2026-07-22
- AI x Bio research should not be treated as one switch, says the post — lemire · 2026-07-22
- mcp-doctor adds CI-friendly health and security audits for MCP servers — sticky_block · 2026-07-22
- Research finds memory compression makes AI agents drop safety rules and hit 59% violations — gerardsans · 2026-07-22